Ormeloxifene

Jump to: navigation, search
Ormeloxifene
Ormeloxifene Wiki Str.png
Clinical data
Trade namesCentron, Novex-DS, Saheli, Sevista
SynonymsCentchroman
Routes of
administration
Oral
ATC code
Pharmacokinetic data
Elimination half-life7 days
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC30H35NO3
Molar mass457.604 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Template:Infobox Birth control

WikiDoc Resources for Ormeloxifene

Articles

Most recent articles on Ormeloxifene

Most cited articles on Ormeloxifene

Review articles on Ormeloxifene

Articles on Ormeloxifene in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ormeloxifene

Images of Ormeloxifene

Photos of Ormeloxifene

Podcasts & MP3s on Ormeloxifene

Videos on Ormeloxifene

Evidence Based Medicine

Cochrane Collaboration on Ormeloxifene

Bandolier on Ormeloxifene

TRIP on Ormeloxifene

Clinical Trials

Ongoing Trials on Ormeloxifene at Clinical Trials.gov

Trial results on Ormeloxifene

Clinical Trials on Ormeloxifene at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ormeloxifene

NICE Guidance on Ormeloxifene

NHS PRODIGY Guidance

FDA on Ormeloxifene

CDC on Ormeloxifene

Books

Books on Ormeloxifene

News

Ormeloxifene in the news

Be alerted to news on Ormeloxifene

News trends on Ormeloxifene

Commentary

Blogs on Ormeloxifene

Definitions

Definitions of Ormeloxifene

Patient Resources / Community

Patient resources on Ormeloxifene

Discussion groups on Ormeloxifene

Patient Handouts on Ormeloxifene

Directions to Hospitals Treating Ormeloxifene

Risk calculators and risk factors for Ormeloxifene

Healthcare Provider Resources

Symptoms of Ormeloxifene

Causes & Risk Factors for Ormeloxifene

Diagnostic studies for Ormeloxifene

Treatment of Ormeloxifene

Continuing Medical Education (CME)

CME Programs on Ormeloxifene

International

Ormeloxifene en Espanol

Ormeloxifene en Francais

Business

Ormeloxifene in the Marketplace

Patents on Ormeloxifene

Experimental / Informatics

List of terms related to Ormeloxifene

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ormeloxifene (also known as centchroman) is one of the selective estrogen receptor modulators,[1] or SERMs, a class of medication which acts on the estrogen receptor. It is best known as a non-hormonal, non-steroidal oral contraceptive which is taken once per week. In India, ormeloxifene has been available as birth control since the early 1990s, and it is currently marketed there under the trade name Saheli.[2] Ormeloxifene has also been licensed under the trade names Novex-DS, Centron and Sevista.

Medical uses

Ormeloxifene is primarily used as a contraceptive but may also be effective for dysfunctional uterine bleeding and advanced breast cancer.[3]

Birth control

Ormeloxifene may be used as a weekly oral contraceptive.[3] The weekly schedule is an advantage for women who prefer an oral contraceptive, but find it difficult or impractical to adhere to a daily schedule required by other oral contraceptives.

For the first twelve weeks of use, it is advised to take the ormeloxifene pill twice per week.[3] From the thirteenth week on, it is taken once per week.[3][4] The consensus is that backup protection in the first month is a cautious but sensible choice. A standard dose is 30 mg weekly, but 60 mg loading doses can reduce pregnancy rates by 38%.[5]

It has a failure rate of about 1-2% with ideal use which is slightly less effective than found for combined oral contraceptive pills.[6]

Other indications

  • Ormeloxifene has also been tested in experimental setting as a treatment for menorrhagia.[7]

Adverse effects

There are concerns that ormeloxifene may cause delayed mensturation.[9]

Method of action

Ormeloxifene is a SERM, or selective estrogen receptor modulator. In some parts of the body, its action is estrogenic (e.g., bones), in other parts of the body, its action is anti-estrogenic (e.g., uterus, breasts.[10][11]) It causes an asynchrony in the menstrual cycle between ovulation and the development of the uterine lining, although its exact mode of action is not well defined. In clinical trials, it caused ovulation to occur later than it normally would in some women,[6] but did not affect ovulation in the majority of women, while causing the lining of the uterus to build more slowly. It speeds the transport of any fertilized egg through the fallopian tubes more quickly than is normal.[6] Presumably, this combination of effects creates an environment such that if fertilization occurs, implantation will not be possible.[6]

Marketing

Ormeloxifene is only legally available in India as of 2009.[12]

Ormeloxifene has been tested and licensed as a form of birth control, as well as a treatment for dysfunctional uterine bleeding. It was first manufactured by Torrent Pharmaceuticals, and marketed as birth control under the trade name Centron. Centron was discontinued. A new license for ormeloxifene was issued to Hindustan Latex Ltd., which now manufactures ormeloxifene as birth control under the trade name Saheli, Novex and Novex-DS. Torrent Pharmaceuticals has resumed manufacture of ormeloxifene under the trade name Sevista, as a treatment for dysfunctional uterine bleeding.

Synthesis

Orme Chem.png

See also

References

  1. Makker, Annu; Tandon, Indu; Goel, Madhu Mati; Singh, Mastan; Singh, Man Mohan (2009). "Effect of ormeloxifene, a selective estrogen receptor modulator, on biomarkers of endometrial receptivity and pinopode development and its relation to fertility and infertility in Indian subjects". Fertility and Sterility. 91 (6): 2298–307. doi:10.1016/j.fertnstert.2008.04.018. PMID 18675966.
  2. "HLL - Product Overview".
  3. 3.0 3.1 3.2 3.3 Lal, J (April 2010). "Clinical pharmacokinetics and interaction of centchroman--a mini review". Contraception. 81 (4): 275–80. doi:10.1016/j.contraception.2009.11.007. PMID 20227542.
  4. http://www.reproline.jhu.edu/english/1fp/1advances/old/1centch/ceorvw.htm
  5. Lal J, Nitynand S, Asthana OP, Nagaraja NV, Gupta RC (January 2001). "Optimization of contraceptive dosage regimen of Centchroman". Contraception. 63 (1): 47–51. doi:10.1016/S0010-7824(00)00189-X. PMID 11257249.
  6. 6.0 6.1 6.2 6.3 Singh, M.M. (2001). "Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders". Medicinal Research Reviews. 21 (4): 302–47. doi:10.1002/med.1011. PMID 11410933.
  7. Kriplani A, Kulshrestha V, Agarwal N (August 2009). "Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study". J. Obstet. Gynaecol. Res. 35 (4): 746–52. doi:10.1111/j.1447-0756.2008.00987.x. PMID 19751337.
  8. Dhar A, Srivastava A (June 2007). "Role of centchroman in regression of mastalgia and fibroadenoma". World J Surg. 31 (6): 1178–84. doi:10.1007/s00268-007-9040-4. PMID 17431715.
  9. Shelly, W (March 2008). "Selective estrogen receptor modulators: an update on recent clinical findings". Obstetrical & gynecological survey. 63 (3): 163–81. doi:10.1097/OGX.0b013e31816400d7. PMID 18279543. Unknown parameter |coauthors= ignored (help)
  10. Gara Rishi Kumar, Konwar Rituraj, Bid Hemant K and MM Singh. In-vitro anti-cancer breast activity of ormeloxifene is mediated via induction of apoptosis and autophagy. 37th annual conference of the endocrine society of India. 30 nov-2 dec, 2007. Abstract p35.
  11. Nigam, Manisha; Ranjan, Vishal; Srivastava, Swasti; Sharma, Ramesh; Balapure, Anil K. (2008). "Centchroman induces G0/G1 arrest and Caspase-dependent Apoptosis involving Mitochondrial Membrane Depolarization in MCF-7 and MDA MB-231 Human Breast Cancer Cells". Life Sciences. 82 (11–12): 577–90. doi:10.1016/j.lfs.2007.11.028. PMID 18279897.
  12. Patil, Robin D. Tribhuwan & Benazir D. (2009). Body image : human reproduction and birth control : a tribal perspective. New Delhi: Discovery Pub. House. p. 20. ISBN 978-81-8356-388-8.

Further reading

  • Ray, Suprabhat; Grover, Payara K.; Kamboj, Ved P.; Setty, B. S.; Kar, Amiya B.; Anand, Nitya (1976). "Antifertility agents. 12. Structure-activity relation of 3,4-diphenylchromenes and -chromans". Journal of Medicinal Chemistry. 19 (2): 276–9. doi:10.1021/jm00224a014. PMID 1249807.

External links


Template:Estrogens Template:Birth control methods


Linked-in.jpg